Alchemy - Issue 28 - Page 16

Landmark grant builds world-class lab The HMSTrust Laboratory was officially opened at MIPS in August. The worldclass translational research facility is the first of its kind in Australia, putting MIPS at the forefront of global health research and development. The development of the new lab was made possible by a landmark $1.2 million grant from the Helen Macpherson Smith Trust. This fostered a further $1.4 million of in-kind contributions from international industry partners PerkinElmer and Shimadzu. This combined support helped leverage an additional $1.5 million, bringing the total to more than $4 million. Some 130 guests – comprising government and industry representatives, donors and senior university staff – attended the official opening by the Victorian Minister for Health, Jill Hennessy. Ms Hennessy said the laboratory would ensure Victoria and Monash remain world leaders in global health. “The HMSTrust Laboratory is a shining example of Victorian research, development and infrastructure having a global impact,” she said. Bringing together Victorian research institutions with international biotech and pharmaceutical organisations, the HMSTrust Laboratory creates a dynamic hub for research and development. Located within the Drug Delivery, Disposition and Dynamics theme at MIPS, the laboratory makes available sophisticated physical and chemical characterisation instruments to support pharmaceutical research and overcome drug development challenges. MIPS director Professor Bill Charman thanked the HMSTrust and industry partners for their support, collaboration and vision in establishing the new facility. “These state-of-the-art facilities and capabilities will support researchers in making 14 the giant translational leap from research to new medicines,” Professor Charman said. “The laboratory will improve global access to life-saving medicines, while providing industryleading training for the next generation of pharmaceutical scientists.” The HMSTrust Laboratory is open to both Monash and external researchers, with systems training and support available for all instruments. The open-access platform will enable home-grown researchers to continue to develop their projects within Australia. The establishment of the lab builds on the success of an earlier HMSTrust grant that enabled MIPS to purchase key analytical equipment in 2007. This equipment, still in use today, enabled early-career researcher Dr Michelle McIntosh to develop the groundbreaking Inhaled Oxytocin Project. This work was the catalyst for establishing the worldclass HMSTrust Laboratory, of which the now Associate Professor McIntosh is director. The global industry partnership between PerkinElmer and Shimadzu is a world first, providing advanced technologies for Victorian pharmaceutical researchers to develop improved global health solutions. HMSTrust